JP7209645B2 - βセクレターゼの阻害のための組成物および方法 - Google Patents

βセクレターゼの阻害のための組成物および方法 Download PDF

Info

Publication number
JP7209645B2
JP7209645B2 JP2019568236A JP2019568236A JP7209645B2 JP 7209645 B2 JP7209645 B2 JP 7209645B2 JP 2019568236 A JP2019568236 A JP 2019568236A JP 2019568236 A JP2019568236 A JP 2019568236A JP 7209645 B2 JP7209645 B2 JP 7209645B2
Authority
JP
Japan
Prior art keywords
weight
composition
baicalein
oroxylin
chrysin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019568236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523342A5 (cg-RX-API-DMAC10.html
JP2020523342A (ja
Inventor
ムハンメド マジード
カリアナム ナガブシャナム
Original Assignee
サミ－サビンサ グループ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サミ－サビンサ グループ リミテッド filed Critical サミ－サビンサ グループ リミテッド
Publication of JP2020523342A publication Critical patent/JP2020523342A/ja
Publication of JP2020523342A5 publication Critical patent/JP2020523342A5/ja
Application granted granted Critical
Publication of JP7209645B2 publication Critical patent/JP7209645B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Confectionery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019568236A 2017-06-15 2018-06-14 βセクレターゼの阻害のための組成物および方法 Active JP7209645B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762520141P 2017-06-15 2017-06-15
US62/520,141 2017-06-15
PCT/US2018/037454 WO2018232063A1 (en) 2017-06-15 2018-06-14 Compositions and methods for beta secretase inhibition

Publications (3)

Publication Number Publication Date
JP2020523342A JP2020523342A (ja) 2020-08-06
JP2020523342A5 JP2020523342A5 (cg-RX-API-DMAC10.html) 2021-07-26
JP7209645B2 true JP7209645B2 (ja) 2023-01-20

Family

ID=64655980

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019568236A Active JP7209645B2 (ja) 2017-06-15 2018-06-14 βセクレターゼの阻害のための組成物および方法
JP2019569247A Active JP6796217B2 (ja) 2017-06-15 2018-06-15 神経保護組成物とその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019569247A Active JP6796217B2 (ja) 2017-06-15 2018-06-15 神経保護組成物とその使用

Country Status (9)

Country Link
US (2) US11458117B2 (cg-RX-API-DMAC10.html)
EP (2) EP3638277B1 (cg-RX-API-DMAC10.html)
JP (2) JP7209645B2 (cg-RX-API-DMAC10.html)
KR (2) KR20190134809A (cg-RX-API-DMAC10.html)
CA (2) CA3063751C (cg-RX-API-DMAC10.html)
ES (1) ES3005508T3 (cg-RX-API-DMAC10.html)
FI (1) FI3638277T3 (cg-RX-API-DMAC10.html)
PL (2) PL3638277T3 (cg-RX-API-DMAC10.html)
WO (2) WO2018232063A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3638277T3 (pl) * 2017-06-15 2025-03-10 Sami Labs Limited Kompozycje i sposoby hamowania beta sekretazy
US12465585B2 (en) * 2018-06-15 2025-11-11 Sami-Sabinsa Group Limited Compositions for the management of seizure induced neurotoxicity
CN110115712A (zh) * 2019-07-04 2019-08-13 兰州大学 一种同时激活氧化磷酸化通路和抑制糖酵解途径的激活剂及其应用
EP4021397A4 (en) * 2019-08-26 2023-09-27 Sami-Sabinsa Group Limited HERBAL ACTIVE INGREDIENTS AND THEIR EFFECT AGAINST POLLUTION
CN114246879B (zh) * 2021-12-30 2023-10-27 沈阳兴齐眼药股份有限公司 木蝴蝶苷b在制备用于预防、控制和/或治疗眼部疾病药物中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504240A (ja) 2003-09-02 2007-03-01 ユニゲン・ファーマシューティカルス・インコーポレーテッド 認知衰退および加齢性記憶障害の予防および処置に用いるためのフリーｂ環フラボノイド類とフラバン類との混合物の製剤
WO2007112288A2 (en) 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
JP2009527541A (ja) 2006-02-21 2009-07-30 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 腸管αグルコシダーゼ阻害剤ならびにその単離方法およびその使用
JP6796217B2 (ja) 2017-06-15 2020-12-02 サミ ラブズ リミテッド 神経保護組成物とその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945518B2 (en) * 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
CA2703698C (en) * 2002-04-30 2016-11-22 Unigen Pharmaceuticals, Inc. Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
US8034387B2 (en) * 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
KR20080091436A (ko) * 2006-01-09 2008-10-13 카운실 오브 사이언티픽 엔드 인더스트리얼 리서치 위장관 독성, 관련 증상 및 궤양 치료용 천연물질
KR20080008929A (ko) * 2006-11-20 2008-01-24 대한민국(관리부서 식품의약품 안전청장) 오록실린 ａ를 함유하는 인지 기능 장애 관련 질환의 예방및 개선용 건강기능식품
EP2890391A4 (en) * 2012-08-29 2016-03-09 Mannkind Corp METHOD AND COMPOSITION FOR TREATING HYPERGLYCEMIA
CA3043168C (en) * 2016-11-11 2021-05-18 Sami Labs Limited Composition containing oroxylin a and method of extraction thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504240A (ja) 2003-09-02 2007-03-01 ユニゲン・ファーマシューティカルス・インコーポレーテッド 認知衰退および加齢性記憶障害の予防および処置に用いるためのフリーｂ環フラボノイド類とフラバン類との混合物の製剤
JP2009527541A (ja) 2006-02-21 2009-07-30 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 腸管αグルコシダーゼ阻害剤ならびにその単離方法およびその使用
WO2007112288A2 (en) 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
JP6796217B2 (ja) 2017-06-15 2020-12-02 サミ ラブズ リミテッド 神経保護組成物とその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Behavioural Brain Research，2016年，Vol.311，pp.309-321
Brain Health Trending at SupplySide West，2015年，[検索日 2022.03.09], online, <URL: https://www.nutritionaloutlook.com/view/brain-health-trending-supplyside-west>
Pure and Applied Chemistry，2017年01月

Also Published As

Publication number Publication date
US20180360800A1 (en) 2018-12-20
JP2020523372A (ja) 2020-08-06
EP3638277A4 (en) 2021-03-17
CA3063757A1 (en) 2018-12-20
JP6796217B2 (ja) 2020-12-02
US11458117B2 (en) 2022-10-04
US10894029B2 (en) 2021-01-19
CA3063751A1 (en) 2018-12-20
EP3638277B1 (en) 2024-10-09
CA3063751C (en) 2023-01-03
PL3638278T3 (pl) 2022-10-03
EP3638278A4 (en) 2021-03-17
KR20190131589A (ko) 2019-11-26
WO2018232063A1 (en) 2018-12-20
PL3638277T3 (pl) 2025-03-10
US20180360801A1 (en) 2018-12-20
EP3638278B1 (en) 2022-05-11
ES3005508T3 (en) 2025-03-14
FI3638277T3 (fi) 2025-01-10
KR20190134809A (ko) 2019-12-04
EP3638277A1 (en) 2020-04-22
WO2018232224A1 (en) 2018-12-20
EP3638278A1 (en) 2020-04-22
JP2020523342A (ja) 2020-08-06
CA3063757C (en) 2023-08-01

Similar Documents

Publication Publication Date Title
Brandebura et al. Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders
CA3063751C (en) Compositions and methods for beta secretase inhibition
Marcelli et al. The involvement of post-translational modifications in Alzheimer's disease
Lahiri et al. Current drug targets for Alzheimer's disease treatment
Porquet et al. Neuroprotective role of trans-resveratrol in a murine model of familial Alzheimer's disease
Buawangpong et al. The role of trimethylamine‐N‐Oxide in the development of Alzheimer's disease
Querfurth et al. Alzheimer's disease
Upadhya et al. Role of the ubiquitin proteasome system in Alzheimer's disease
McGeer et al. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
Galimberti et al. Disease-modifying treatments for Alzheimer’s disease
Zhang Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer’s disease
Niranjan Molecular basis of etiological implications in Alzheimer’s disease: focus on neuroinflammation
Prasad et al. Prostaglandins as putative neurotoxins in Alzheimer's disease
Ziegler-Waldkirch et al. The role of glial cells and synapse loss in mouse models of Alzheimer’s disease
Sun et al. Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives
Chiba Emerging therapeutic strategies in Alzheimer's disease
Acewicz et al. Incidence and morphology of secondary TDP-43 proteinopathies: Part 1
Yates et al. The molecular pathology of Alzheimer’s disease
JP2020523342A5 (cg-RX-API-DMAC10.html)
Wang et al. Raw Inonotus obliquus polysaccharide counteracts Alzheimer’s disease in a transgenic mouse model by activating the ubiquitin-proteosome system
Luque et al. The molecular and cellular pathogenesis of dementia of the Alzheimer's type: an overview
Hou et al. Tetrahydroxystilbene glucoside improves learning and (or) memory ability of aged rats and may be connected to the APP pathway
Erdemci et al. Etiology and histopathology of alzheimer’s disease and current approaches
Ling et al. The recent updates of therapeutic approaches against aβ for the treatment of Alzheimer's disease
Froelich-Fabre et al. Mechanisms of tauopathies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210604

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230110

R150 Certificate of patent or registration of utility model

Ref document number: 7209645

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250